Naming and strategy news

Camargo Launches New Brand at GPhA as 505(b)(2)

04 feb 2015

From www.businesswire.com – February 4, 2015 Camargo Pharmaceutical Services, will reveal its new brand at the Generic Pharmaceutical Association (GPhA) Annual Meeting. The FDA 505)b)(2) application A 505(b)(2) is a new drug application which contains full safety and effectiveness reports, but allows at least some of the information required for approval to come from studies not... read more


FDA Tries to End Dispute Between Brand-Name and Generic Drug Makers

04 dec 2014

From www.blogs.wsj.com – December 4, 2014 The FDA is trying to bring brand name and generic drug makers together after vociferous complaints from generic drug makers that their brand-name counterparts have been exploiting an FDA risk-mitigation program, which is designed to boost patient safety, in order to thwart generic competition. “The FDA has issued a so-called... read more


Record breaking new drug approvals

01 jun 2014

From: http://www.evaluategroup.com/ – June 1, 2014 Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D that has kept expenditure growth below sales growth proves that the industry is turning a new corner according to the latest edition of EvaluatePharma’s World Preview report – view infographic here (PDF). EvaluatePharma® is the leader in consensus forecasts... read more


Making medicine emotional – Medical Marketing and Media

01 jun 2014

Megan Hillen on www.mmm-online.com – June 1, 2014: “Medical Marketing and Media Making medicine emotional Medical Marketing and Media How can pharma brands be “more human”?” Interesting article about how brands can personify a tangible thing into something powerfully intangible. A strong brand decommoditizes a commodity because it lives in our heads and in our hearts. read more


New drug approvals in ICH countries 2004-2013

19 apr 2014

From: Centre for Innovation in Regulatory Science (CIRS) – April, 2014 In 2013, the overall number of New Active Substances (NASs) approved by EMA, FDA and PMDA was comparable across the three agencies. This briefing looks specifically at trends in the number of approvals and approval times across the following agencies: European Centralised, US FDA... read more


How Big Pharma is “humanising” its brands

05 feb 2014

From www.pharmatimes.com – February 5, 2014 How Big Pharma is “humanising” its brands PharmaTimes Major pharmaceutical companies are beginning to embrace the “brand personality” marketing strategy traditionally employed by consumer-focused companies such as Apple, Coca-Cola and Harley-Davidson, new research shows. What can pharma brands learn from fmcg brands in their battle against private labels and... read more


As biosims win nods in Europe and India, debate over naming rights …

29 jan 2014

From www.fiercepharma.com – January 29, 2014 What’s in a name? In the pharmaceutical world, the answer to this question is no simple matter. Drugmakers, biotechs and their generic rivals are squabbling over the names that will be assigned to biosimilars, in a battle for a marketing edge. Should biosimilars have the same International Proprietary Names... read more


Drug patent cliff to drive pharma firms into innovation, research

24 jan 2014

From businessdayonline.com – January 24, 2014 Drug patent cliff to drive pharma firms into innovation, research BusinessDay The generic drug industry covers the marketing and sale of medication containing the same active ingredients and dosages as brand-name drugs manufactured by the… read more


What’s in a name? Just about everything

19 jan 2014

From www.thenational.ae – January 19, 2014 What’s in a name? Just about everything Nigerian pharmaceutical companies have been successful in building brand identity in the country. Translating an international brand into a household name is vital to a company’s success in Africa, particularly as brand loyalty is typically high in the continent. “Once companies win... read more


Trade-name Drugs vs. Generic Drugs | Health Article Directory

13 jan 2014

From filmws.org – January 13, 2014 The difference between these two versions is that brand-name medication is manufactured by a certain pharmaceutical company that held a patent on the drug. Having a patent on particular medicine implies that other companies don’t possess the right to sell it. – Facts about generic drugs. (From: http://www.fda.gov) read more


Why Don’t You Trust Generic Drugs as Much as Brand Name Medicines?

13 jan 2014

From www.peoplespharmacy.com – January 13, 2014 Why don’t patients and their doctors trust generic drugs? Despite the fact that 84 percent of all prescriptions are dispensed in their generic form, there is still a great deal of skepticism about the quality of these less expensive medications. (Research in Social and Administrative Pharmacy, Nov-Dec, 2012) A... read more


Novartis and Merck: “Wanna Trade?” Companies Propose to Swap Businesses

10 jan 2014

From wallstcheatsheet.com – January 10, 2014 Novartis and Merck: “Wanna Trade?” Companies Propose to Swap Businesses Wall St. read more


A guide for international pharmaceutical communications: What do we really mean by brand value? (Part 1)

04 mei 2012

From www.pharmaphorum.com – May 4, 2012 Sunil Ramkali presents some key insights on how to deliver a brand that truly addresses market needs in the pharmaceutical industry. Is developing differentiated brand communications that deliver real world value and drive brand uptake your goal? read more


Double Trouble: Consumer awareness of look-alike names

01 jan 2010

Consumer awareness of look-alike names is critical for drug safety From www.consumermedsafety.org – January 1, 2010 Coming up with a name for a new medicine isn’t as easy as you think. Drug companies look for names that scream ‘take me’ to fix what ails you. The name also needs to stick in your doctor’s mind so it... read more